Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Cancer Immunol Immunother. 2016 Sep 10;65(11):1411–1421. doi: 10.1007/s00262-016-1900-z

Figure 5. HDACs alter CD1d-mediated antigen presentation through cell-extrinsic mechanisms.

Figure 5

a STAT3 was immunoprecipitated from JeKo-1 cell lysates using three different STAT3 monoclonal antibodies (mAbs) and the immunoprecipitates were evaluated for presence of HDAC2. b ChIP was performed to determine whether STAT3 binds the CD1d promoter at proximal and distal sites, with interferon response factor 1 (IRF1) serving as a positive control. c JeKo-1 and Sp53 were treated with 1 μM TSA for 24 hours and the cytokine concentrations in supernatants were assessed by LEGENDPlex Human Inflammation Panel assay. d JeKo-1 and Sp53 cells were treated with 1 μM TSA for 24 hours and IL-10 levels in supernatants were confirmed by standard ELISA. Positive control is P/I. e LCD1d were treated with IL-10 to induce STAT3 and co-cultured with DN32.D3 and N38-3C3. T-tests were performed to demonstrate statistical significance: * p < 0.05 and ***p<0.0001.